AOA Dx

AOA Dx Inc has partnered with a leading researcher at McGill University to develop the first early stage ovarian cancer liquid biopsy diagnostic test. The co-founders have worked together at two previous startups in the women’s health space, both resulting in successful exits upon commercialization. Ovarian cancer is the deadliest gynecological disease because there is no accurate testing method and therefore its symptoms are continuously mistaken for benign conditions, making it incredibly difficult to diagnose the disease in the early stages. The team has previously raised a $7M Seed round and completed a 500+ retrospective patient study showing excellent sensitivity and specificity. Ovarian cancer is just the beginning. AOA has a platform of novel ganglioside tumor markers to disrupt early cancer detection.